Modality
Bispecific Ab
MOA
GLP-1ag
Target
IL-17A
Pathway
Wnt
MCLFabry
Development Pipeline
Preclinical
~Jul 2015
→ ~Oct 2016
Phase 1
Jan 2017
→ Nov 2028
Phase 1Current
NCT03569640
1,974 pts·Fabry
2017-01→2025-05·Terminated
NCT08799303
2,663 pts·Fabry
2017-08→2028-11·Recruiting
4,637 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-05-2210mo agoInterim· Fabry
2028-11-132.6y awayInterim· Fabry
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1
Termina…
P1
Recruit…
Catalysts
Interim
2025-05-22 · 10mo ago
Fabry
Interim
2028-11-13 · 2.6y away
Fabry
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03569640 | Phase 1 | Fabry | Terminated | 1974 | MRD |
| NCT08799303 | Phase 1 | Fabry | Recruiting | 2663 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| ILM-5680 | Illumina | Phase 2 | BET | |
| RVM-7089 | Revolution Medicines | Phase 3 | IL-17A | |
| CRS-184 | CRISPR Therapeutics | Phase 1/2 | AHR |